Have a feature idea you'd love to see implemented?
Let us know!
USNA Usana Health Sciences Inc
Price (delayed)
$36.78
Market cap
$700.74M
P/E Ratio
12.82
Dividend/share
N/A
EPS
$2.87
Enterprise value
$368.32M
USANA prides itself in providing consumers the highest quality nutritional products in the world. From its award-winning supplements to its innovative skincare line, USANA has proven for more than 25
Highlights
USNA's debt has plunged by 100% from the previous quarter and by 100% YoY
The price to earnings (P/E) is 21% lower than the last 4 quarters average of 16.5 and 17% lower than the 5-year quarterly average of 15.7
USNA's net income is down by 13% year-on-year and by 11% since the previous quarter
The EPS has contracted by 13% YoY and by 11% from the previous quarter
Key stats
What are the main financial stats of USNA
Market
Valuations
Earnings
Shares outstanding
19.05M
Market cap
$700.74M
Enterprise value
$368.32M
Price to earnings (P/E)
12.82
Price to book (P/B)
1.37
Price to sales (P/S)
0.8
EV/EBIT
3.89
EV/EBITDA
3.19
EV/Sales
0.42
Revenue
$875.12M
EBIT
$94.75M
EBITDA
$115.56M
Free cash flow
$59.29M
Per share
Balance sheet
Liquidity
EPS
$2.87
Free cash flow per share
$3.11
Book value per share
$26.89
Revenue per share
$45.88
TBVPS
$30.72
Total assets
$631.42M
Total liabilities
$119.21M
Debt
$0
Equity
$512.21M
Working capital
$315.19M
Debt to equity
0
Current ratio
4.03
Quick ratio
3.2
Net debt/EBITDA
-2.88
Margins
Efficiency
Dividend
EBITDA margin
13.2%
Gross margin
80.8%
Net margin
6.3%
Operating margin
9.6%
Return on assets
8.8%
Return on equity
11.1%
Return on invested capital
67%
Return on capital employed
18%
Return on sales
10.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
USNA stock price
How has the Usana Health Sciences stock price performed over time
Intraday
-1.39%
1 week
0.55%
1 month
-3.01%
1 year
-20.39%
YTD
-31.38%
QTD
-3.01%
Financial performance
How have Usana Health Sciences's revenue and profit performed over time
Revenue
$875.12M
Gross profit
$706.87M
Operating income
$84.34M
Net income
$55.08M
Gross margin
80.8%
Net margin
6.3%
USNA's net income is down by 13% year-on-year and by 11% since the previous quarter
The operating income has declined by 13% year-on-year and by 7% since the previous quarter
USNA's net margin is down by 9% from the previous quarter and by 6% YoY
USNA's revenue is down by 8% year-on-year and by 2.8% since the previous quarter
Growth
What is Usana Health Sciences's growth rate over time
Valuation
What is Usana Health Sciences stock price valuation
P/E
12.82
P/B
1.37
P/S
0.8
EV/EBIT
3.89
EV/EBITDA
3.19
EV/Sales
0.42
The price to earnings (P/E) is 21% lower than the last 4 quarters average of 16.5 and 17% lower than the 5-year quarterly average of 15.7
The EPS has contracted by 13% YoY and by 11% from the previous quarter
USNA's P/B is 59% below its 5-year quarterly average of 3.4 and 31% below its last 4 quarters average of 2.0
The company's equity rose by 3% YoY and by 2.4% QoQ
USNA's price to sales (P/S) is 38% less than its 5-year quarterly average of 1.3 and 26% less than its last 4 quarters average of 1.1
USNA's revenue is down by 8% year-on-year and by 2.8% since the previous quarter
Efficiency
How efficient is Usana Health Sciences business performance
The ROE has contracted by 18% YoY and by 12% from the previous quarter
The company's return on invested capital fell by 17% YoY and by 9% QoQ
Usana Health Sciences's ROA has decreased by 15% YoY and by 11% from the previous quarter
The ROS has contracted by 4.4% from the previous quarter
Dividends
What is USNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for USNA.
Financial health
How did Usana Health Sciences financials performed over time
The quick ratio has grown by 15% YoY and by 10% from the previous quarter
The current ratio has increased by 14% YoY and by 8% from the previous quarter
USNA's debt is 100% less than its equity
USNA's debt has plunged by 100% from the previous quarter and by 100% YoY
The company's equity rose by 3% YoY and by 2.4% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.